Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.52 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.47 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.45 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.45 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.44 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30794819 | 1.00 | CHRNA7 (0.52) | CHRNA7KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL5676107 | 0.89 | CHRNA7 (0.39) | CHRNA7KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL30796524 | 0.89 | CHRNA7 (0.39) | CHRNA7KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL5847724 | 0.82 | CHRNA7 (0.55) | CHRNA7KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL30795745 | 0.82 | CHRNA7 (0.55) | CHRNA7KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL15807217 | 0.80 | KCNQ3 (0.57) | CHRNA7KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL15799207 | 0.77 | KCNQ3 (0.72) | CHRNA7KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL5849183 | 0.77 | CYP3A4 (0.47) | CHRNA7CYP3A4ROCK2PRKG1 | |
| SCHEMBL30795863 | 0.77 | CYP3A4 (0.47) | CHRNA7CYP3A4ROCK2PRKG1 | |
| SCHEMBL5888661 | 0.75 | ENPP2 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144881-B2 | Arylcyclopropylcarboxylic amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-05 | — | — | US | claimed |
| US-20040110754-A1 | 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide for example; for pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | claimed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-7144881-B2 | Arylcyclopropylcarboxylic amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| US-20040110754-A1 | 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide for example; for pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110754-A1 | 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide for example; for pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders | KCNQ2, KCNQ5, KCNJ2 | CHRNA7 148/4885KCNQ3 5/4885KCNQ2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.